AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03651271 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab and Ipilimumab (3 mg/kg) Combination for Prostate Cancer
Description: For nivolumab and ipilimumab combination therapy, CD8 low arm, approximately 10 participants will be randomly allocated into 1 of 2 cohorts, using different doses of ipilimumab administered in 6-week cycles. Participants assigned to Prostate Cohort A will receive nivolumab 1 mg/kg Q3W and ipilimumab 3 mg/kg every 6 weeks (Q6W) for 2 cycles, then nivolumab maintenance 480 mg Q4W until PD or intolerable toxicity. If the safety profile of Prostate Cohort B is deemed unacceptable, an additional 10 participants will be enrolled in Prostate Cohort A.
Study NCT03651271 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab and Ipilimumab (5 mg/kg) Combination for Prostate Cancer
Description: For nivolumab and ipilimumab combination therapy, CD8 low arm, approximately 10 participants will be randomly allocated into 1 of 2 cohorts, using different doses of ipilimumab administered in 6-week cycles. Participants assigned to Prostate Cohort B will receive nivolumab 1 mg/kg Q3W and ipilimumab 5 mg/kg Q6W for 2 cycles, then nivolumab maintenance 480 mg Q4W until PD or intolerable toxicity. If Prostate Cohort B is determined to have a tolerable safety profile, an additional 10 participants will be enrolled to receive nivolumab 1 mg/kg Q3W and ipilimumab 5 mg/kg Q6W for 2 cycles, then nivolumab maintenance 480 mg Q4W until PD or intolerable toxicity.
Study NCT04704245 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: epidermal growth factor (EGF)-containing ointment
Description: The subjects applied the epidermal growth factor (EGF) ointment twice daily (morning and evening) to the lesion for 4 weeks after laser treatment.
Study NCT04704245 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle ointment
Description: To compare the effect of epidermal growth factor (EGF) ointment, the control subjects applied the vehicle ointment twice daily (morning and evening) to the lesion for 4 weeks after laser treatment.
Study NCT04704245 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Q-swithced (QS) 532-nm Nd:yttrium aluminum garnet (YAG) laser
Description: The subjects received one session of laser treatment with a Q-swithced (QS) 532-nm Nd:yttrium aluminum garnet (YAG) laser of their solar lentigines after enrollment.~The procedure parameters were as follows: 5-10-ns pulse duration, 3.5-mm spot size, 0.9-1.1-J/cm2 fluence, and 2-Hz frequency.~The end point of laser treatment for lentigines was immediate whitening.
Study NCT04704245 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Q-swithced (QS) 532-nm Nd:yttrium aluminum garnet (YAG) laser
Description: The subjects received one session of laser treatment with a Q-swithced (QS) 532-nm Nd:yttrium aluminum garnet (YAG) laser of their solar lentigines after enrollment.~The procedure parameters were as follows: 5-10-ns pulse duration, 3.5-mm spot size, 0.9-1.1-J/cm2 fluence, and 2-Hz frequency.~The end point of laser treatment for lentigines was immediate whitening.
Study NCT01902017 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketotifen
Description: 5 mg PO bid
Study NCT03778190 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Corneal Foreign Body Removal
Description: An eye magnet will be brought close to the foreign body on the surface of the eye in an attempt to remove the foreign body.
Study NCT01467401 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: biphasic insulin aspart
Description: Individually adjusted dose. Injected subcutaneously (s.c., under the skin) twice daily
Study NCT01467401 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: biphasic human insulin
Description: Individually adjusted dose. Injected subcutaneously (s.c., under the skin) twice daily
Study NCT01247753 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Walking group
Description: Internet-mediated pedometer-based walking program with gradually increasing step count goals and feedback on step counts. Also includes nutritional coaching course consisting of 1 individual session with a dietician, 4 group sessions, and monthly follow-up. Oral glucose tolerance tests pre and post-intervention.
Study NCT03852407 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thymoglobulin
Description: ATG: 2.5 mg /kg/day on day -2 and -1 (day 0 is allogenic transplantation)
Study NCT03852407 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: 100mg/m² on day -2
Study NCT03852407 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 30mg/m² on days -6, -5, -4, -3, and -2
Study NCT03852407 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamid
Description: 50 mg/kg on days +3 and +4.
Study NCT03567200 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Single-Arm Feasibility
Description: Participants in each of the 8 participating groups (N=10-12 per group) are exposed to an integrated intervention program (integration of physical activity and psychosocial components). Each session is co-facilitated by a trained research staff member and a registered social worker, providing participants with the opportunity to engage in physical activity behaviours as well as discuss various psychosocial topics that are applicable to the participants interests. Physical activities include participating in group activities such as rock climbing, self-defence, yoga, etc. Psychosocial topics addressed include group discussions around cyber-bullying, sexual abuse and exploitation, gender issues, etc.
Study NCT02260752 — intervention group
Intervention type: PROCEDURE
Intervention: hysterectomy
Description: surgical removal of the uterus
Study NCT02260752 — intervention group
Intervention type: PROCEDURE
Intervention: Uterine arterial embolization
Description: In uterine artery embolization, doctor uses a slender, flexible tube (catheter) to inject small particles (embolic agents) into the uterine arteries, which supply blood to your fibroids and uterus.the embolic agents are injected into these fibroid blood vessels. The goal is to block the fibroid vessels, starving the fibroids and causing them to shrink and die.
Study NCT02260752 — intervention group
Intervention type: PROCEDURE
Intervention: myomectomy
Description: surgical procedure to remove uterine fibroids, but does not remove uterus
Study NCT02260752 — intervention group
Intervention type: DRUG
Intervention: Medical Therapy
Description: treatment of uterine fibroids with only medications, no procedure or surgery is used
Study NCT02260752 — intervention group
Intervention type: PROCEDURE
Intervention: endometrial ablation
Description: surgical procedure that destroys uterine lining via a telescope placed inside the uterus
Study NCT02260752 — intervention group
Intervention type: PROCEDURE
Intervention: magnetic resonance guided focused ultrasound
Description: procedure that destroys fibroids while inside an MRI machine
Study NCT02260752 — intervention group
Intervention type: PROCEDURE
Intervention: radiofrequency ablation
Description: procedure that uses heat to destroy uterine fibroids
Study NCT03797339 — intervention group
Intervention type: OTHER
Intervention: risk factors of adverse cardiovascular events
Description: During the follow-up period,general information(age, sex, BMI, blood pressure, the history of drink and smoke, medical history, etc).Blood biochemistry parameters（Lipid, hsCRP levels, etc）and other laboratory examination parameters will be collected
Study NCT03797339 — intervention group
Intervention type: OTHER
Intervention: multi-omics target discovery
Description: Genome-wide genotype , DNA methylation and metabolomes were determined using illumina high-density genotyping chips, high-throughput sequencing, and high-resolution mass spectrometry respectly. Blood exposure of statins and metoprolol and its metabolites was determined by UPLC-MS/MS.
Study NCT03797339 — intervention group
Intervention type: OTHER
Intervention: validation
Description: The genome-wide genotype of patients with coronary heart disease was detected using the illumina chip. The methylation level of the functional region was detected by the target region enrichment methylation sequencing method. Intestinal flora differences were detected using 16SrDNA high-throughput sequencing.
Study NCT03797339 — intervention group
Intervention type: OTHER
Intervention: Predictive mathematical models
Description: Machine learning algorithms such as multiple linear regression or Bayesian classification are used to optimize clinical factors and multi-group targets to establish predictive mathematical models.
Study NCT02404779 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisatracurium besilate
Study NCT02404779 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01413152 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: blood and semen sampling, specific biological exams and biobank and self administered questionnaires
Description: blood and semen sampling, specific biological exams and biobank and self administered questionnaires
Study NCT03456973 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nurse AMIE
Description: Supportive care software platform
Study NCT01339000 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glycosylated Recombinant Human Interleukin-7
Description: Interleukin-7 (CYT 107) 20 microgram/kg / dose, by intramuscular (IM) injection
Study NCT01339000 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Diphtheria/Tetanus Vaccine
Description: Diphtheria/Tetanus Vaccine will be administered according to the random schedule per protocol.
Study NCT01339000 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Polio Vaccine
Description: Polio Vaccine will be administered according to the randomized schedule per protocol.
Study NCT01339000 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pneumococcal Vaccine
Description: Pneumococcal Vaccine will be administered according to the randomization schedule per protocol.
Study NCT01339000 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Hepatitis A Vaccine
Description: Hepatitis A Vaccine will be administered according to the randomization schedule per protocol.
Study NCT01339000 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Hepatitis B Vaccine
Description: Hepatitis B vaccine will be administered according to the randomization schedule per protocol.
Study NCT00741117 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Arterial Blood Gas
Description: One blood gas sample will be obtained from an artery in the arm.
Study NCT00741117 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pulse Oximetry Machine
Description: A pulse oximetry machine will be used at one time point to obtain an oxygen saturation reading. This is done by placing a clip onto the finger. The pulse oximetry value displays on the pulse oximeter machine within seconds.
Study NCT00741117 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Direct and Indirect Serum Bilirubin Measurement
Description: One tube of blood will be drawn from a vein in the arm at one timepoint to measure the direct and indirect serum bilirubin levels.
Study NCT04626882 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Staged in-hospital or Immediate complete revascularization
Description: Patients with ST-segment elevation myocardial infarction and multivessel disease will be randomized after primary PCI for IRA. All patients will be randomized to immediate complete revascularization group or staged revascularization group by 1:1 fashion. Non-IRA lesion which have equal or more than 70% diameter stenosis by visual estimation will be revascularized without FFR evaluation. Non-IRA lesion with diameter stenosis 50-70% by visual estimation will be evaluated using FFR device. In case of FFR value more than 0.8, non-IRA lesion wll be deferred without PCI. If FFR value was equal or less than 0.8, non-IRA lesion will be revascularized.
Study NCT04626882 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Staged in-hospital or Immediate complete revascularization
Description: Patients with ST-segment elevation myocardial infarction and multivessel disease will be randomized after primary PCI for IRA. All patients will be randomized to immediate complete revascularization group or staged revascularization group by 1:1 fashion. Non-IRA lesion which have equal or more than 70% diameter stenosis by visual estimation will be revascularized without FFR evaluation. Non-IRA lesion with diameter stenosis 50-70% by visual estimation will be evaluated using FFR device. In case of FFR value more than 0.8, non-IRA lesion wll be deferred without PCI. If FFR value was equal or less than 0.8, non-IRA lesion will be revascularized.
Study NCT01387360 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Supracor
Description: The presbyopic treatment consists of a standard treatment for distance vision and the procedure known as SUPRACOR addition to correct near vision.~The SUPRACOR addition provides a multifocal ablation with a central near addition with an aberration controlled transition zone towards the periphery, thereby allowing good focus over a range of object distances.
Study NCT03422796 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cilostazol 200mg
Description: Cilostazol is given both study days to induce headache. One day the headache is treated with placebo and the other day with sumatriptan
Study NCT03422796 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cilostazol 200mg
Description: Cilostazol is given both study days to induce headache. One day the headache is treated with placebo and the other day with sumatriptan
Study NCT03422796 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SUMAtriptan 6 MG/ML
Description: Cilostazol is given both study days to induce headache. One day the headache is treated with placebo and the other day with sumatriptan
Study NCT03422796 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Cilostazol is given both study days to induce headache. One day the headache is treated with placebo and the other day with sumatriptan
Study NCT03974516 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Careseng 1370
Description: Careseng 1370 should be taken around 1 hour before meal.
Study NCT03692286 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Calcium Hydroxide Intracanal medication
Description: Calcium hydroxide intracanal medication
Study NCT04255576 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dietary Supplement: Calcium/Vitamin D
Description: All subjects should be adequately supplemented with calcium and vitamin D (at least 500 mg of calcium and 400 IU of vitamin D), except in the case of pre-existing hypercalcemia.
Study NCT00101270 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan hydrochloride
Description: Given IV
Study NCT00101270 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin
Description: Given IV
Study NCT02442947 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: clothing type, protective garments of Paul Boye Technologies
Description: The experiment aimed at evaluating the physiological stress obtained when dressed in different clothing (NBC protective garment \[charcoal base\], combat garment and 2 different types of work uniforms- (1)50% cotton and 50% polyester (2)80% cotton and 20% polyester) and during exertion under heat conditions.
Study NCT03671161 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Insulin Pump and flash glucose monitoring
Description: Adults with type 1 diabetes, HbA1c >9% (75 mmol/mol), multi daily insulin injections ( MDI) and who perform less than 2 SMBG /day. Patients will be switched to insulin pump and start a FGM system (Free Style Libre®) during 6 months.
Study NCT04653038 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MGD013
Description: A fixed dose of MGD013 600mg IV Q2W will be administered to subjects
Study NCT01870687 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 20mg VAC BNO 1095 FCT
Study NCT01870687 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01161706 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vegetable Juice
Description: Participants consumed vegetable juice daily in the amount of 0, 8 or 16 fluid ounces.
Study NCT01902017 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 5 mg placebo PO bid
Study NCT01982916 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGR tablet
Study NCT01982916 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (for AGR tablet and/or Active Comparator)
Study NCT01982916 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo (for AGR tablet and/or Active Comparator)
Study NCT01982916 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (for AGR tablet and/or Active Comparator)
Study NCT01982916 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Active Comparator
Study NCT01411189 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Menthol
Description: 20 mL NPO-11 in prefilled syringe
Study NCT01033747 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deferasirox
Description: 10 mg/kg or 30 mg/kg orally daily
Study NCT01033747 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deferasirox
Description: 5 mg/kg or 30 mg/kg orally daily
Study NCT01431066 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Sham pulsed radio-frequency electromagnetic device
Description: Disabled PRFE device
Study NCT01431066 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ActiPatch PRFE Device
Description: Actipatch PRFE device
Study NCT02940470 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Calorie restricted diet plus exercise
Description: Daily meals plus exercise providing 1000 kcal restriction per day for 12 weeks.
Study NCT02940470 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Weight management classes
Description: Weekly 1-hour weight management classes for 12 weeks.
Study NCT02306915 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lipegfilgrastim
Description: lipegfilgrastim 30 μg/kg, 60 μg/kg, 100 μg/kg
Study NCT03575130 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ripasudil eye drops
Description: Rho-kinase-Inhibitor (IMP)
Study NCT03575130 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Optive eye drops
Description: Artificial tears (placebo)
Study NCT03575130 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Descemetorhexis
Description: Corneal endothelial cells are removed prior to IMP administration by Descemetorhexis.
Study NCT03575130 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Descemetorhexis
Description: Corneal endothelial cells are removed prior to IMP administration by Descemetorhexis.
Study NCT00003498 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antineoplaston therapy (Atengenal + Astugenal)
Description: Patients with Non-Hodgkin's Lymphoma will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1.
Study NCT02881281 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: educational program for Development of problem-solving skills
Study NCT02881281 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: no education program
Description: no education program
Study NCT00701389 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: telcagepant potassium
Description: Single oral dose of 2 x 300 mg capsules.
Study NCT00701389 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sumatriptan
Description: single oral dose of 100 mg sumatriptan
Study NCT00701389 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sumatriptan placebo
Description: single oral dose
Study NCT00701389 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: telcagepant potassium placebo
Description: single oral dose of 2 MK-0974 placebo capsules
Study NCT01055639 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: In-Person ACT
Description: 8 individual in-person sessions of Acceptance and Commitment Therapy (ACT): includes mindfulness, values, and committed action
Study NCT01055639 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telehealth ACT
Description: 8 individual telehealth sessions of Acceptance and Commitment Therapy (ACT): includes mindfulness, values, and committed action
Study NCT03324061 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant for Injectable Suspension
Description: Test drug is administered as a single 5mL intramuscular injection in the right or left dorsogluteal muscle area
Study NCT03324061 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Faslodex (Reference)
Description: Reference drug is administered as two 5mL intramuscular injections, one in each of the right and left dorsogluteal muscle areas
Study NCT01993719 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aldesleukin
Description: 720,000 IU/kg intravenous (IV) every eight hours (+/- 1 hour) beginning within 24 hours of cell infusion and continuing for up to 4 days (maximum 12 doses).
Study NCT01993719 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 25 mg/m\^2/day intravenous piggy-back (IVPB) daily for 5 days
Study NCT01993719 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 30 mg/kg/day intravenous piggy-back (IVPB) daily for 3 days.